Management with a track record in innovation
Before joining Opsona Therapeutics, Martin Welschof was the Managing Director and co-founder of Affitech A/S, a biopharmaceutical company listed on the Nasdaq OMX Copenhagen stock exchange. Affitech A/S is a human antibody company with product focus primarily in cancer and inflammation and having proprietary technologies in the discovery and early stage development of human antibodies.
Prior to joining Affitech A/S, Martin Welschof was the Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, which he joined in 1997 during its start-up phase. From 1999 until 2002 he led Axaron’s technology department and was responsible for the R&D process related to a large portfolio of cutting-edge technologies in the field of transcription analysis and functional genomics.
During that time he worked at Axaron’s parent company, LYNX Therapeutics Inc., Hayward, California, where he coordinated the process development of LYNX massive parallel cloning and sequencing technologies MegaClone, MegaSort and MPSS.
Martin Welschof did his post-doctoral training at the German Cancer Research Center's Department for Recombinant Antibody Technology and the University of Heidelberg's Department of Transplantation Immunology, both in Heidelberg, Germany (1996 to 1997). He has a Ph.D. (Dr.rer.nat.) in the field of recombinant antibody technology from the University of Bielefeld, Germany.
Mary Reilly joined the Opsona management team in March 2005 to head up the pharmaceutical development of its pre-clinical candidates.
Her role is to direct the development of lead compounds from discovery through pharmaceutical development including chemistry, manufacturing and controls (CMC) and their progression into the clinic.
She has extensive experience in drug development from late-stage discovery to registration and approval of products at all stages of the development cycle within Europe and the USA.
Before joining Opsona she worked for 15 years with Elan Pharmaceuticals where she was Associate Director and Project Leader for development projects. She also has experience in parenteral sterile drug development, manufacture and registration.
Mary Reilly currently oversees programme management, pharmaceutical and clinical development and operational activities. She has QP qualifications in line with EU clinical directive 2001/20/EC.
Conor Dalton was appointed Director of Finance in November 2011.
Prior to joining Opsona, he held the position of Vice-President, Finance and Principal Accounting Officer of Amarin Corporation plc from 2005 to January 2010. Since January 2010, he continued to provide consultancy services to Amarin and start-up pharma company Dignity Sciences Limited. He also acted as Company Secretary for Dignity.
Prior to Amarin, he spent approximately nine years with Elan Corporation plc, holding various roles in Ireland and North America, most recently as Director of Finance.
He is a fellow of the Association of Chartered Certified Accountants.
Luke O’Neill is a co-founder and director of Opsona Therapeutics. He was appointed to the Chair of Biochemistry at Trinity College Dublin in 2008, where he leads the Inflammation Research Group. In the same year, he was appointed Chair of the Immunity and Infection panel of the European Research Council. His research is in the area of the molecular basis to inflammatory diseases, with a particular interest in pro-inflammatory cytokines and Toll-like receptors.
He has a PhD in Pharmacology from the University of London and has won numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, the Irish Society for Immunology medal, the Royal Dublin Society/ Irish Times Boyle medal for Scientific Excellence and the Science Foundation Ireland Researcher of the Year Award 2009. He was elected a member of EMBO (the European Molecular Biology Organization) in 2005.
He has published over 200 papers and reviews on his research, in journals such as Nature, Science, Cell, Nature Immunology, Nature Medicine, Nature Genetics and PNAS. His contribution to the field of immunology in Ireland and internationally can be seen from Ireland’s recent ranking as third in the world in terms of citations per paper (1999-2009), where seven of his publications were ranking in the top nine from Ireland since 2006.
Dr Robert M Miller
Consultant Chief Medical Officer
Robert Miller is the Chief Consultancy Physician for Aptiv Solutions providing medical input into the strategy and design of development programmes in multiple indications. He has worked with Opsona since 2006 on clinical strategy and joined as their consultant Chief Medical Officer in November 2011.
Dr Miller trained as a cardiac surgeon and joined the pharmaceutical industry as a medical adviser with ICI in 1988. He moved into the international division in 1990 taking responsibility for the global development of products in three therapeutic areas including cardiovascular and intensive care. In 1996 he joined Protodigm Limited, the virtual company set up by Roche, as a founder member and was Director of Clinical Development and was a founder and Chief Medical Officer of Fulcrum Pharma PLC an independent product development consultancy.
Dr Miller is a Fellow of the Royal College of Surgeons, The Royal Society of Medicine, and is a Fellow of the Faculty of Pharmaceutical Medicine. He qualified as a physician in 1975 from The London Hospital (England) and has medical degrees from the University of London as well as the Royal Colleges of Surgeons and Physicians of England.